Kardigan (KARD) Raises $400 Million in Expanded IPO to Accelerate Phase 3 Trials for its Cardiovascular Pipeline
MyoKardia Founders Reunited, IPO Oversubscribed with $400 Million
Kardigan (KARD) finalized its Nasdaq IPO on June 17, 2026, at $16 per share (the upper end of the $14-$16 range), increasing the number of shares offered from 23.3 million to 25 million, raising a total of $400 million. This exceeds the original target of $350 million by 14%. The company was founded by Tassos Gianakakos, CEO, and Bob McDowell, CSO, both of whom were instrumental in the success of MyoKardia, which was acquired by BMS (BMY) for $13.1 billion. Their track record in developing mavacamten, a cardiac myosin inhibitor, has been a key factor in securing the trust of institutional investors. J.P. Morgan, Jefferies, Leerink Partners, and TD Securities served as joint book-running managers.
Three Cardiovascular Pipelines and Funding Allocation Strategy
The lead program, danicamtiv (MYK-491, a cardiac myosin activator), is currently in a Phase 2b/3 adaptive trial (KINSHIP-DCM) for patients with hypertrophic cardiomyopathy (HCM) caused by MYH7/TTN gene mutations, with topline data expected in the first half of 2027. Ataciguat (a soluble guanylate cyclase activator, originally developed by Sanofi/Mayo Clinic) is in a Phase 3 trial (KATALYST-AV) for moderate aortic valve stenosis (AVS), enrolling 1,400 patients. Phase 2 data showed a reduction of more than 50% in valve calcium. Tonlamarsen (an antisense oligonucleotide targeting angiotensinogen, originally developed by Ionis Pharmaceuticals) showed a 67% reduction in plasma AGT at ACC.26, but the additional blood pressure-lowering effect of multiple doses was minimal, so the indication is being switched to acute severe hypertension. Funding will be allocated as follows: $80 million to $90 million for danicamtiv, $80 million to $90 million for ataciguat, $40 million to $50 million for tonlamarsen, and $50 million to $60 million for other R&D.
Market Opportunity: First-in-Class Potential for Both HCM and AVS
The market for HCM treatments is projected to grow to $3.2 billion to $4.6 billion by 2030, and if approved, danicamtiv will be the first small-molecule therapy specifically for HCM. Currently, there are no drug treatments for AVS, with surgical valve replacement (TAVR/SAVR) being the only option, creating a significant opportunity for ataciguat as a first-in-class therapy. The overall market for aortic stenosis treatments is expected to grow from approximately $11.3 billion in 2026 to $22.9 billion in 2033. In terms of competition, gene therapy approaches from companies like Rocket Pharmaceuticals (RCKT) and Tenax Therapeutics (TENX) are still in the early stages for HCM.
Company Finances and 2027 as a Pivotal Year
The company was listed with a valuation of $1.3 billion to $1.4 billion and had cumulative funding of $570 million prior to the IPO (including a $254 million Series B round). As of March 31, 2026, the company had $287 million in cash. Net loss for the 12-month period was $230 million, with R&D expenses of $153 million (an 80% increase year-over-year). Despite having no revenue, the company has attracted top-tier healthcare investors, including Perceptive Advisors, ARCH Venture Partners, Sequoia Heritage, Fidelity, and T. Rowe Price. The simultaneous data readouts for all three programs in the first half of 2027 are expected to be a key catalyst for revaluation. The company is the 13th biotech company to go public in 2026, and the market environment, which has already surpassed the total number of biotech IPOs in 2025 (11), reflects a recovery in liquidity.
Kardigan's $400 million expanded IPO is one of the largest biotech IPOs of 2026, and institutional investors have assigned a $1.3 billion to $1.4 billion premium valuation to the company, reflecting the track record of the MyoKardia founders (mavacamten → $13.1 billion acquisition by BMS). Both HCM and AVS represent opportunities for first-in-class therapies, as there are currently no approved drug treatments for either condition, and the simultaneous data readouts for all three pipelines in the first half of 2027 are expected to be a key catalyst for valuation. The 50%+ reduction in valve calcium observed in the Phase 2 trial of ataciguat and the initiation of the KATALYST-AV Phase 3 trial suggest that ataciguat has the potential to be the first drug option for the $11.3 billion aortic stenosis treatment market. However, the lack of blood pressure-lowering effect with tonlamarsen carries program pivot risk, and given the company's cash burn rate of $230 million over the past 12 months, the success of the 2027 data will be a key determinant of whether the company can secure additional funding.
Source: FierceBiotech (rss)